BioCryst Pharmaceuticals BCRX Financing Lease, Expense
Financing Lease, Expense at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:FinancingLeaseExpense.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's financing lease, expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's financing lease, expense?
- BioCryst Pharmaceuticals (BCRX) reported financing lease, expense of $441K in Q1 2026.
- How has BioCryst Pharmaceuticals's financing lease, expense changed year-over-year?
- BioCryst Pharmaceuticals's financing lease, expense decreased by 30.2% year-over-year, from $632K to $441K.
- What is the long-term trend for BioCryst Pharmaceuticals's financing lease, expense?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's financing lease, expense has grown at a 106.2% compound annual growth rate (CAGR), from $135K to $2.44M.
- What does financing lease, expense mean?
- This captures the total periodic costs associated with financing leases, including both the depreciation of the underlying asset and the interest expense on the lease liability. It provides a comprehensive view of the burden placed on the income statement by long-term financing arrangements for leased assets. Investors use this to assess the company's fixed-cost structure.